Prospective non-interventional study finds ruxolitinib safe and effective in patients with polycythaemia vera, suggesting its use as a second-line treatment.
/µl). There was almost no difference in the total number of thromboembolic events in JAK inhibitor naïve versus JAK inhibitor pretreated patients (3.1%, n = 5 versus 3.8%, n = 10). No new safety concerns were observed with ruxolitinib. Findings from this study in a real-world setting show that ruxolitinib is an effective and safe second-line treatment in PV patients.
No takes yet. Share an insight, caveat, or question.
Grießhammer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: